Makalot profits surge
Makalot Industrial Co (聚陽), a diversified garment manufacturer that counts global brands and major clothing retailers among its customers, on Friday said that its pretax profits for the first five months of the year totaled NT$884 million (US$29.28 million). The figure represents a 25.47 percent increase from the profits Makalot reported in the same period last year. With 170 million outstanding shares, the company’s pretax profit for the first five months translated into earnings per share of NT$5.2, marking a rise from the NT$4.18 per share that it earned a year earlier. The clothing manufacturer’s cumulative revenue from January through last month totaled NT$8.08 billion, representing a 16.62 percent year-on-year rise, Makalot said.
OBI cancer trials nearly done
OBI Pharma Inc (台灣浩鼎) is expected to soon completed data collection for phase-three clinical trials of a new breast cancer drug, OBI-822, the drug manufacturer told shareholders on Friday. OBI Pharma is likely to publish the results of the trials in the next six to nine months, chairman Michael Chang (張念慈) said at an annual general meeting. In February, the company said it plans to file for a permit to sell OBI-822 locally in 2016 and in the US in 2018, with plans to launch the cancer drug in the US, Taiwan and China on its own, but with a partner in Europe and Japan. General manager Amy Huang (黃秀美) also reiterated the pharmaceutical firm’s plans to shift its listing to the GRETAI Securities Market from the Emerging Stock Market by the end of this year. The company has not yet filed an application with regulators to get approval for the change.